Revenue decline and widening losses are the key negatives for a pre-commercial biotech. The $516.6M cash position provides a long runway, but the burn rate is accelerating. Watch for upcoming data readouts from GB-0895 Phase 3 and GB-4362 Phase 1 as potential catalysts. The IPO overhang may still be digesting given the recent March 2 pricing.
Price Chart
Executive Summary
Generate Biomedicines reported Q1 2026 collaboration revenue of $7.2M (down 18% YoY from $8.8M) and a net loss of $61.7M, wider than the $44.3M loss in Q1 2025. The company ended the quarter with $516.6M in cash after its March IPO, providing runway into H1 2028, but the widening loss and revenue decline are the headline financials for a pre-revenue biotech.
Key Financial Metrics
Key Facts
- Q1 2026 collaboration revenue $7.2M vs $8.8M in Q1 2025, an 18% YoY decline
- Net loss widened to $61.7M from $44.3M in the prior-year quarter
- Cash, cash equivalents, and marketable securities of $516.6M as of March 31, 2026, up from $221.5M at year-end 2025, reflecting $369.3M in net IPO proceeds
- Cash runway guided into first half of 2028; company expects to require additional capital for long-term operations
- R&D expenses rose to $57.8M from $46.8M, driven by Phase 3 investment in GB-0895 and personnel costs
- GB-0895 (anti-TSLP) Phase 3 trials SOLAIRIA-1 and SOLAIRIA-2 in severe asthma are advancing; Phase 1b in COPD ongoing
- GB-4362 (MMAE neutralizer) received FDA Fast Track designation; first patient dosing expected mid-2026
- GB-5267 (MUC16 armored CAR T) first patient dosing expected H2 2026 in Phase 1 solid tumor trial
Financial Impact
Revenue declined $1.6M YoY (18%); net loss increased $17.4M (39%); operating cash burn increased to $80.4M from $53.2M
Risk Factors
- No approved products or recurring revenue stream; entirely dependent on partnership collaboration revenue
- Accelerating cash burn ($80.4M operating cash outflow in Q1) may require future dilutive financing
- Phase 3 clinical trial risk for GB-0895; failure would remove the most advanced pipeline asset
- Competition from established anti-TSLP therapies (e.g., Tezspire) in severe asthma
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-209899 |
| Document: ck0002100782-20260507.htm | 0001193125-26-209899 |
| Document: 0001193125-26-209899-index-headers.html | 0001193125-26-209899 |
| Document: 0001193125-26-209899-index.html | 0001193125-26-209899 |
| Document: 0001193125-26-209899.txt | 0001193125-26-209899 |
| 8-K Data (Synthetic) | 0001193125-26-209899 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 7, 2026 21w ago | 8-K | $13.59 $14.34 | ▼ −5.52% | ▼ −1.69% | $13.43 (+1.18%) |
Mar 2, 2026 30w ago | Insider Cluster | $12.17 $13.34 | ▲ +9.61% | ▲ +0.29% | $13.43 (+10.35%) |
Mar 2, 2026 30w ago | Insider Cluster | $12.17 $13.34 | ▲ +9.61% | ▲ +0.29% | $13.43 (+10.35%) |
Feb 27, 2026 30w ago | 424B4 | $12.17 $13.34 | ▼ −9.61% | ▼ −0.29% | $13.43 (−10.35%) |
Feb 27, 2026 31w ago | EFFECT | $12.65 $13.34 | ▲ +5.45% | ▼ −3.93% | $13.43 (+6.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access